What type of study is this?

This is a Animal Study study (also classified as: In Vitro Study).

What question did this study set out to answer?

The research aims to evaluate the therapeutic efficacy of momelotinib and LP-182 in myelofibrosis models.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

The research aims to evaluate the therapeutic efficacy of momelotinib and LP-182 in myelofibrosis models.
Utilized in vitro SET-2 cells to determine IC50 values for LP-182, momelotinib, and their combination.
Employed MRI for assessing spleen volume changes in a mouse model of JAK2-mutant myelofibrosis.
Grouped treatment cohorts: vehicle, LP-182, momelotinib, and combination for 28 days.
LP-182 demonstrated a lower IC50 for proliferation inhibition at 14.4 mm compared to momelotinib at 0.13 mm.
Combination therapy showed significant reductions in spleen volume compared to single-agent treatments.
Significant reductions in phosphorylated STAT5 were noted with momelotinib treatment, while LP-182 normalized phosphorylated AKT and ERK levels.

No takes yet. Share an insight, caveat, or question.

Combination therapy shows enhanced therapeutic strategy for reducing fibrosis in myelofibrosis, indicating potential for improved outcomes.

Ross et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Combination therapy shows enhanced therapeutic strategy for reducing fibrosis in myelofibrosis, indicating potential for improved outcomes.